返回
Bayesian unsupervised clustering identifies clinically relevant osteosarcoma subtypes
DOI:10.1093/bib/bbae665.png)
摘要
En 中文
Identification of cancer subtypes is a critical step for developing precision medicine. Most cancer subtyping is based on the analysis of RNA sequencing (RNA-seq) data from patient cohorts using unsupervised machine learning methods such as hierarchical cluster analysis, but these computational approaches disregard the heterogeneous composition of individual cancer samples. Here, we used a more sophisticated unsupervised Bayesian model termed latent process decomposition (LPD), which handles individual cancer sample heterogeneity and deconvolutes the structure of transcriptome data to provide clinically relevant information. The work was performed on the pediatric tumor osteosarcoma, which is a prototypical model for a rare and heterogeneous cancer. The LPD model detected three osteosarcoma subtypes. The subtype with the poorest prognosis was validated using independent patient datasets. This new stratification framework will be important for more accurate diagnostic labeling, expediting precision medicine, and improving clinical trial success. Our results emphasize the importance of using more sophisticated machine learning approaches (and for teaching deep learning and artificial intelligence) for RNA-seq data analysis, which may assist drug targeting and clinical management.
Keyword:
heterogeneity
latent process decomposition
osteosarcoma
precision medicine
RNA-seq
AI总结
对已上传原文的论文进行重点信息的提取,主要内容包括:简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
7.7
论文数:
5.8K
被引数:
2.7W
机构
暂无机构信息
引用论文
Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children?s Oncology Group复发性骨肉瘤患者抗对话神经节苷脂抗体dinutuximab联合gm-csf的2期研究: 儿童肿瘤学小组的报告
Comparative Transcriptome Analysis Quantifies Immune Cell Transcript Levels, Metastatic Progression, and Survival in Osteosarcoma
CANCER RESEARCH
IF16.6
A Bayesian model for unsupervised detection of RNA splicing based subtypes in cancers
NATURE COMMUNICATIONS
IF15.7
The early evolutionary landscape of osteosarcoma provides clues for targeted treatment strategies
JOURNAL OF PATHOLOGY
IF5.2
Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma
CELL REPORTS
IF6.9
Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma
CANCER
IF5.1

